Evidence map›Paper›PMID 42235930›Full record

ArticleThe Journal of antimicrobial chemotherapy2026

Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus.

Gen Li, Ibrahim M El-Deeb, Hayden G Whyte, Mark A T Blaskovich, Mark J Walker, Mark von Itzstein, David M P De Oliveira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gen LiAustralian Infectious Diseases Research Centre, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Ibrahim M El-DeebInstitute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4222, Australia.
Hayden G WhyteAustralian Infectious Diseases Research Centre, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Mark A T BlaskovichCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Mark J WalkerAustralian Infectious Diseases Research Centre, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Mark von ItzsteinInstitute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4222, Australia.
David M P De OliveiraAustralian Infectious Diseases Research Centre, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.

Funding

National Health and Medical Research Council of Australia APP1176180National Health and Medical Research Council of Australia GNT1196520National Health and Medical Research Council of Australia GNT2009677National Health and Medical Research Council of Australia GNT2014388The University of Queensland Research Training
6 · The paper itself

Abstract

BACKGROUND AND

objectivesEnterococcus faecium and Staphylococcus aureus are opportunistic bacterial pathogens with a demonstrated capacity to develop antimicrobial resistance and cause serious life-threatening infections, underscoring the urgent need for new therapeutic options.

methodsHere, we have synthesized and characterized the activities of an 8-hydroxyquinoline-based ionophore antibiotic (ionophoroantibiotic; IP antibiotic), designated 'IP-antibiotic 12.'

resultsUsing multidrug-resistant strains of E. faecium and S. aureus, in vitro investigations revealed that IP-antibiotic 12 exhibits bactericidal activity, demonstrates a low propensity for resistance emergence, increases the susceptibility of particular strains to select antibiotics, possesses a favorable toxicity profile, and dysregulates bacterial metal homeostasis. IP-antibiotic 12 demonstrated therapeutic efficacy against multidrug-resistant S. aureus skin infection, as a direct-acting topical antimicrobial and antibiotic adjunct when co-administered with oral linezolid. Interestingly, it was not efficacious in murine models of systemic and pulmonary infection.

conclusionsThese results highlight the potential of IP-antibiotic 12 as a novel therapeutic against multidrug-resistant gram-positive bacteria and provide a foundation for the development of next-generation IP-antibiotics with enhanced in vivo therapeutic efficacy.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialEnterococcus faeciumIonophoresOxyquinolineStaphylococcus aureusAnimalsDisease Models, AnimalFemaleGram-Positive Bacterial InfectionsMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsIonophoresOxyquinoline

Identifiers

PMID42235930
PMCPMC13232504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.